Cell Systems’ primary human retinal microvascular endothelial cells (HRMECs, ACBRI 181) and retinal pericytes (ACBRI 183) are optimized for blood-retinal barrier (BRB) modeling, angiogenesis, and retinal microvascular research applications.
These early passage, antibody-free cells are validated in high-impact studies for expression of key endothelial markers including CD31, VEGF, Ang-2, CCL2, NG2, and relevant regulatory RNAs. Applications include retinal permeability modeling, barrier function assays, transendothelial resistance testing, and 3D microvascular-on-chip studies.
With proven performance in co-culture, permeability, and gene expression assays, these primary human cells are ideal for 2D/3D research culture systems, organ-on-chip platforms, and blood-retinal barrier studies.
Key Features:
- Early passage cells, Passage 3 (<12 population doublings)
- Antibody-free isolation
- High viability (~85%), 1M cells per vial
- Supports 2D/3D culture, organ-on-chip, and co-culture
- Shipped as frozen vials or proliferating flasks
- Consistency across long-term studies with deep inventory from a single donor lot.
